James Boylan
Chief Executive Officer @ Enavate Sciences
New York, United States
James Boylan is a seed investor at Enavate Sciences in New York focused on Therapeutics and Biotechnology. James Boylan
- Total investments:
- 4
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries James Boylan invests in
Stages James Boylan invests in
Countries James Boylan invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Therapeutics 3 (75%)
- Biotechnology 3 (75%)
- Biopharma 2 (50%)
Stage
- Seed 1 (25%)
- Series B 1 (25%)
- Private Equity 1 (25%)
- Post-IPO Equity 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Graviton Bioscience is a clinical-stage drug discovery and development firm focused on creating and developing therapies for the treatment of CNS, autoimmune, fibrotic, and other significant disorders in which ROCK2 plays a critical role in pathology. | Seed / Jan 02, 2024 | ||
| Graviton Bioscience is a clinical-stage drug discovery and development firm focused on creating and developing therapies for the treatment of CNS, autoimmune, fibrotic, and other significant disorders in which ROCK2 plays a critical role in pathology. | $25M / Private Equity / Jan 02, 2024 | ||
| Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeuticsthat can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. | $80M / Post-IPO Equity / Nov 02, 2022 | ||
| CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients. | $100M / Series B / Jul 20, 2022 |
Co-Investors
About Enavate Sciences
Enavate Sciences is committed to investing in and supporting the strategic growth of innovative therapeutic and enabling technology companies.
Enavate Sciences Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Christine Del Corsano
Chief Financial Officer
|
|||
Edd Fleming
Executive Vice President, Commercialization
|
|||
|
James Boylan
Chief Executive Officer
|
|||
Robert Glassman
EVP, Search and Evaluation
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does James Boylan invest in?
James Boylan invests primarily in Therapeutics, Biotechnology and Biopharma startups, most often at Seed and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact James Boylan?
Public channels for James Boylan include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did James Boylan last invest?
The most recent investment recorded for James Boylan closed in Jan 2024. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
